Loading
Tirzepatide / Guided self-help cognitive behavioral therapy / Binge Eating Disorder · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 clinical trial registration comparing tirzepatide against placebo and lisdexamfetamine for binge-eating disorder in adults with obesity. The study is currently recruiting and has not yet reported results. No outcome data are available to evaluate efficacy or safety.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Obesity and Overweight, Binge Eating Disorder; age from 18 Years. Intervention: Tirzepatide. Compared with: Lisdexamfetamine dimesylate — Active Comparator; Placebo — Placebo Comparator. n = 105. 1 site: United States.
This is a Phase 2 clinical trial registration comparing tirzepatide against placebo and lisdexamfetamine for binge-eating disorder in adults with obesity. The study is currently recruiting and has not yet reported results. No outcome data are available to evaluate efficacy or safety.
No efficacy, safety, or comparative effect data are available from this source.
The source did not state who this applies to in practice.
Phase 2 trial registration with no results posted; study is actively recruiting and designed to assess efficacy and safety of tirzepatide in binge-eating disorder.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06847399). This is a study registration, not published results. Lead sponsor: Johns Hopkins University. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 105 participants (ESTIMATED). Conditions: Obesity and Overweight, Binge Eating Disorder. Interventions: DRUG: Tirzepatide; DRUG: Lisdexamfetamine Dimesylate; BEHAVIORAL: Guided self-help cognitive behavioral therapy; DRUG: Placebo (oral); DRUG: Placebo (injection). Primary outcome measures: Percent initial weight loss , Baseline to 52 weeks; Change in the Number of Binge-eating episodes , Baseline to 52 weeks. Brief summary: The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.